echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > PD-L1-CTLA-4 bispecific antibodies developed by Corning Jerry are about to enter clinical trials.

    PD-L1-CTLA-4 bispecific antibodies developed by Corning Jerry are about to enter clinical trials.

    • Last Update: 2020-08-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On October 11, Jiangsu Corning Jerry Biopharmaceutical Co., Ltd. ("Jiangsu Corning Jerry") announced that its independent research and development of the world's first recombinant humanized PD-L1-CTLA-4 bispecific antibodies (product code: KN046) has recently conducted Phase I clinical trials in Australia, and has received clinical approval from the State Drug Administration of China, which is about to enter clinical trials in China.
    The success of the development of cancer immunoantibodies drugs over the past decade marks a major breakthrough in the history of anti-cancer research, and the 2018 Nobel Prize in Medical Physiology has been awarded to two scientists who have made outstanding contributions to research and development in this field.
    PD-(L)1 and CTLA-4 are currently the only two cancer immunopharmaceutical targets that have been proven to be effective in clinical trials, but the approved PD-(L)1 and CTLA-4 antibody drugs are only effective in some cancer patients;
    Jiangsu Corning Jerry from the safety of the in-depth consideration, screening out a new generation of CTLA-4 antibodies, improve their safety, and pD-L1 antibody fusion to form a dual-target antibody KN046.
    through protein engineering, KN046 is targeted and concentrated in the pD-L1 high-expression tumor microenvironment, thereby further reducing the possible toxic side effects of the human peripheral system.
    in preclinical studies, KN046 showed good anti-tumor efficacy, and compared with existing CTLA-4 antibodies, the toxic side effects were greatly reduced. "KN046 is the world's first-of-its-kind tumor immuno-immune dual-target therapy antibody, and we target it at the cornerstone of second-generation tumor immunotherapy," said Dr. Xu Wei, chairman of the
    Jiangsu Corning Jerry's.
    we are very pleased to see that THE FIRST phase of the TRIAL of KN046 in Australia is progressing well and has reached the expected therapeutic dose.
    we expect the overall treatment indicators of KN046 to be better than pD-(L) 1 or CTLA-4 antibody monodrug, as well as the combination of these two antibody drugs. Dr. Xu,
    ", added: "Based on KN046's unique mechanism of action, excellent preclinical research and CMC testing indicators, it took 3 months for the China Pharmaceutical Review Center to approve and approve the clinical approval."
    We are very grateful to the National Drug Administration for its recognition and support for the KN046 project and have communicated and discussed the KN046 clinical trial plan with international oncologists.
    we plan to develop multiple tumor indications simultaneously in the near future, and push the KN046 project at full speed to reach cancer patients in China and around the world at an early date.
    " Source: BioBAY.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.